H. Cheng, O. K. Reavis, J. M. Grisar
Dec 1, 1980
Citations
0
Influential Citations
23
Citations
Quality indicators
Journal
Life sciences
Abstract
Abstract Medroxalol is a new antihypertensive agent with combined α- and β-adrenergic receptor blocking properties. We have examined the antihypertensive and adrenergic receptor blocking properties of the enriched medroxalol enantiomers in the spontaneously hypertensive rat (SHR) and α1 and β1-adrenergic blocking activities in vitro . The four enantiomers, designated as (+)A, (−)A and (+)B, (−)B, exhibited significant antihypertensive activity in SHR of nearly equal potency. The (+) enantiomers exhibited greater α-antagonism and the (−) enantiomers, greater β-antagonism than their antipodes. Other mechanisms, in addition to α- and β-adrenergic receptor blockade, may have contributed to the antihypertensive action of medroxalol and its enantiomers.